Ultragenyx Pharmaceutical RARE Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $175M-58.4% | $421M+108% | $202.51M+14.9% | $176.31M+38.8% | $127M-27.0% | ||
| $238M-8.1% | $259M+16.3% | $222.74M-28.4% | $311.28M-15.3% | $367.39M-15.7% | ||
| $121M-23.4% | $158M+40.4% | $112.54M-9.6% | $124.46M+25.9% | $98.84M-19.0% | ||
| $55M+5.8% | $52M-0.4% | $52.2M+12.3% | $46.5M+1.0% | $46.03M+2.3% | ||
| $657M-30.9% | $951M+47.9% | $643.21M-10.6% | $719.79M+3.0% | $699.16M-14.4% | ||
| $239M-2.0% | $244M-2.4% | $249.96M-2.3% | $255.76M-2.0% | $260.91M-1.9% | ||
| $44M0.0% | $44M-0.9% | $44.41M0.0% | $44.41M0.0% | $44.41M+0.9% | ||
| $174M-1.1% | $176M+1.8% | $172.94M-1.0% | $174.73M-1.0% | $176.52M-0.8% | ||
| $1.3B-15.4% | $1.53B+28.7% | $1.19B-8.9% | $1.31B-0.4% | $1.31B-12.7% | ||
| $325M-15.4% | $384M+12.9% | $340.02M+16.0% | $293.24M+0.5% | $291.67M-15.2% | ||
| $1.53B-5.0% | $1.61B+36.7% | $1.17B+2.3% | $1.15B-1.1% | $1.16B-6.5% | ||
| $0— | $0-100% | $96K0.0% | $96K+2.1% | $94K— | ||
| -$4.72B-4.1% | -$4.53B-2.9% | -$4.4B-4.3% | -$4.22B-2.8% | -$4.11B-3.8% | ||
| -$236M-195% | -$80M-973% | $9.16M-93.9% | $151.29M+5.1% | $144M-43.5% | ||
| $1.3B-15.4% | $1.53B+28.7% | $1.19B-8.9% | $1.31B-0.4% | $1.31B-12.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Ultragenyx Pharmaceutical cover its short-term obligations?
- Its current ratio is 2.02 — current assets exceed current liabilities.
- Where does Ultragenyx Pharmaceutical's balance sheet data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.